1. The Evolution of Therapies in Non-Small Cell Lung Cancer
   Vishal Boolell et al, 2015, Cancers CrossRef
2. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
   J.C.-H. Yang et al, 2016, Annals of Oncology CrossRef
3. Cancers bronchiques non à petites cellules mutés ou réarrangés : de la premiere á la énième ligne
   J. Raimbourg et al, 2015, Revue des Maladies Respiratoires Actualités CrossRef
4. The Efficacy and Safety of Gefitinib in Elderly Patients with Epidermal Growth Factor Receptor Mutation-positive Advanced Non-small Cell Lung Cancer
   Kei Kusaka et al, 2016, Haigan CrossRef
5. Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study
   Jing-Ren Ye et al, 2022, Frontiers in Surgery CrossRef
6. Clinical significance of plasma free DNA in patients with non-small cell lung cancer
   Lanxiang Ma et al, 2019, Journal of International Medical Research CrossRef
7. Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids
   Mostafa Ghorab et al, 2016, Molecules CrossRef